CureVac Future Growth
Future criteria checks 0/6
CureVac's revenue and earnings are forecast to decline at 34.4% and 27.1% per annum respectively. EPS is expected to decline by 27.2% per annum. Return on equity is forecast to be -30.1% in 3 years.
Key information
-27.1%
Earnings growth rate
-27.22%
EPS growth rate
| Biotechs earnings growth | 23.9% |
| Revenue growth rate | -34.4% |
| Future return on equity | -30.09% |
| Analyst coverage | Good |
| Last updated | 16 May 2025 |
Recent future growth updates
Recent updates
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
May 01
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Mar 28CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Jan 08Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
Jan 04CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 165 | -36 | 57 | N/A | 3 |
| 12/31/2026 | 100 | -95 | -20 | N/A | 6 |
| 12/31/2025 | 70 | -104 | 60 | N/A | 7 |
| 12/31/2024 | 535 | 162 | 83 | 102 | N/A |
| 9/30/2024 | 304 | -77 | -115 | -86 | N/A |
| 6/30/2024 | 66 | -278 | -330 | -290 | N/A |
| 3/31/2024 | 59 | -273 | -312 | -265 | N/A |
| 12/31/2023 | 54 | -260 | -323 | -268 | N/A |
| 9/30/2023 | 43 | -302 | -335 | -273 | N/A |
| 6/30/2023 | 38 | -301 | -325 | -249 | N/A |
| 3/31/2023 | 50 | -291 | -338 | -249 | N/A |
| 12/31/2022 | 67 | -249 | -379 | -286 | N/A |
| 9/30/2022 | 97 | -122 | -527 | -420 | N/A |
| 6/30/2022 | 115 | -219 | -758 | -659 | N/A |
| 3/31/2022 | 117 | -313 | -782 | -673 | N/A |
| 12/31/2021 | 103 | -412 | -861 | -733 | N/A |
| 9/30/2021 | 68 | -468 | -228 | -109 | N/A |
| 6/30/2021 | 44 | -361 | N/A | N/A | N/A |
| 3/31/2021 | 56 | -219 | 250 | 329 | N/A |
| 12/31/2020 | 49 | -129 | 475 | 522 | N/A |
| 9/30/2020 | 50 | -107 | 36 | 62 | N/A |
| 3/31/2020 | 17 | -102 | -82 | -67 | N/A |
| 12/31/2019 | 17 | -100 | -99 | -87 | N/A |
| 12/31/2018 | 13 | -71 | -89 | -74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVAC's earnings are forecast to decline over the next 3 years (-27.1% per year).
Earnings vs Market: CVAC's earnings are forecast to decline over the next 3 years (-27.1% per year).
High Growth Earnings: CVAC's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CVAC's revenue is expected to decline over the next 3 years (-34.4% per year).
High Growth Revenue: CVAC's revenue is forecast to decline over the next 3 years (-34.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVAC is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 09:25 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CureVac N.V. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Martin Auster | Credit Suisse |